Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 36th Annual Piper Sandler Healthcare Conference in New York, NY.
華盛頓州溫哥華和紐約，2024年11月21日（全球新聞通訊）-- Absci公司（納斯達克：ABSI），一家以數據爲第一的生成性人工智能藥物創造公司，今天宣佈該公司將參加即將在紐約市舉行的第36屆年派傑投資醫療會議。
Absci's Founder & CEO Sean McClain is scheduled to participate in a panel discussion titled "The Promise of AI in Drug Development" on Thursday, December 5th at 2:00 p.m. Eastern Time.
Absci的創始人兼首席執行官肖恩·麥克萊恩定於12月5日（星期四）東部時間下午2點參與一場名爲「人工智能在藥物開發中前景」的小組討論。
Interested parties may contact their Piper Sandler representative to request registration details for this live event.
有興趣的各方可以聯繫他們的派傑投資代表，申請此直播活動的註冊詳情。
About Absci
關於Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Absci是一家將人工智能與可擴展實驗室技術相結合的數據導向的生成AI藥物研發公司，旨在更快地爲患者創建更好的生物製品。我們的綜合藥物創新平台通過同時優化開發和治療效益的多個藥物特性，釋放加速臨床時間並增加成功率的潛力。憑藉訓練數據、人工智能和溼實驗驗證，我們可以每週篩選數十億個細胞，從AI設計的抗體到溼實驗驗證的候選藥物只需短短六週。Absci的總部位於華盛頓溫哥華市，AI研究實驗室位於紐約市，創新中心位於瑞士楚格。 平台可以解鎖潛力，加速到達臨床階段的時間，並通過同時優化多種對開發和治療效果重要的藥物特性來增加成功的可能性。有數據用於訓練，人工智能用於創建，溼實驗室用於驗證，我們可以每週篩查數十億個細胞，使我們能夠在短短六週內從人工智能設計的候選藥物轉變爲溼實驗室驗證的候選藥物。Absci的總部位於華盛頓州溫哥華，我們的人工智能研究實驗室位於紐約市，創新中心位於瑞士蘇黎世。訪問 ，以及 Twitter(@Abscibio)@absci，以及 Twitter(@Abscibio)@Abscibio）以及YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
投資者聯繫人
Alex Khan
財務與投資者關係副總裁
investors@absci.com
Media Contact
press@absci.com
媒體聯繫
press@absci.com
譯文內容由第三人軟體翻譯。
